Dysregulation of GLP-1R signaling contributes to impaired insulin secretion, altered lipid homeostasis, hyperglycemia, and metabolic dysfunction observed in obesity and type 2 diabetes [1]
Evoke and Evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimers disease
What the Phase 2 Trial Data Shows According to data reviewed by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), understanding clinical trial parameters is essential when setting expectations for any weight management medication
In my clinical experience, side effects are a common reason people discontinue GLP-1 treatment, said Dr